Comment on: Butler et al. Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors. Diabetes 2013;62:2595-2604.

Szczegóły
Comments

Tytuł:: Comment on: Butler et al. Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors. Diabetes 2013;62:2595-2604.
Autorzy:: Heine RJ; Lilly Research Laboratories and Lilly Diabetes, Eli Lilly & Co., Indianapolis, Indiana.
Fu H
Kendall DM
Moller DE
Źródło:: Diabetes [Diabetes] 2013 Oct; Vol. 62 (10), pp. e16-7.
Typ publikacji:: Journal Article; Comment
Język:: English
Imprint Name(s):: Publication: Alexandria, VA : American Diabetes Association
Original Publication: [New York, American Diabetes Association]
MeSH Terms:: Diabetes Mellitus, Type 2/*drug therapy
Incretins/*therapeutic use
Insulin-Secreting Cells/*drug effects
Pancreas/*drug effects
Female ; Humans ; Male
References:: Diabetes. 2013 Jul;62(7):2595-604. (PMID: 23524641)
Am J Physiol Endocrinol Metab. 2010 Dec;299(6):E1076-86. (PMID: 20923958)
Am J Physiol Endocrinol Metab. 2012 Jul 15;303(2):E253-64. (PMID: 22589391)
Diabetes Obes Metab. 2013 May;15(5):417-26. (PMID: 23163898)
Diabetes. 2010 Jul;59(7):1702-8. (PMID: 20413508)
Virchows Arch. 2005 Nov;447(5):800-5. (PMID: 16021508)
Am J Surg Pathol. 2006 Jan;30(1):36-41. (PMID: 16330940)
Diabetes. 2012 May;61(5):1250-62. (PMID: 22266668)
Substance Nomenclature:: 0 (Incretins)
Entry Date(s):: Date Created: 20130926 Date Completed: 20131210 Latest Revision: 20211021
Update Code:: 20240104
PubMed Central ID:: PMC3781464
DOI:: 10.2337/db13-0690
PMID:: 24065798
: Czasopismo naukowe

Comment on: Diabetes. 2013 Jul;62(7):2595-604. (PMID: 23524641)
Comment in: Diabetes. 2013 Oct;62(10):e19-22. (PMID: 24065800)

Informacja